TXG

Ark Invest’s Q3 report lists 10x Genomics as a top performer, while Tesla and RKLB were among the biggest losers. The report highlights how these stocks contributed to the performance of Ark’s ETFs.

Analysts raised 10x Genomics’ fair value estimate by about 22%, citing increased demand for AI and interest in the Atera spatial biology platform. The update reflects a shift in expectations for the company’s newer products.

What a fantastic six months it’s been for 10x Genomics. Shares of the company have skyrocketed 187%, hitting $72.70. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the third quarter ended September 30, 2026 after market close on Thursday, November 5, 2026.

TD Cowen keeps a Hold rating on 10x Genomics and lifts its price target from $47 to $70, indicating a more optimistic outlook.

Morgan Stanley maintains an Equal‑Weight rating on 10x Genomics and raises its price target from $40 to $70, suggesting stronger upside potential.

Canaccord Genuity keeps a Buy rating on 10x Genomics and boosts its price target from $60 to $100, pointing to significant upside.

10x Genomics shares rose 6.1% after Bank of America increased its price target to $80 from $50 while keeping a Neutral rating.